Global Cancer Technology Licenses Autophagy Modulators from Neuropore Therapies
GLOBAL CANCER TECHNOLOGY LICENSES AUTOPHAGY MODULATORS FROM NEUROPORE THERAPIES FOR TREATMENT OF CANCERS AND OTHER LIFE-THREATING DISEASES
SAN DIEGO, December 10, 2020 – Global Cancer Technology, Inc. announced today that it has licensed from Neuropore Therapies, LLC, two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy. This portfolio of autophagy modulators, targeting PI3K and VPS34, was discovered and characterized by Neuropore Therapies using its platform of autophagy and lysosomal biogenesis cellular assays.
Mr. John Clark, founder and CEO of Global Cancer Technology, commented, “Modulators of autophagy have therapeutic potential in a wide range of diseases including cancers, metabolic and neurodegenerative disorders." Mr. Clark further added, "We are excited to explore the therapeutic potential of the P13K and VPS34 targeted compounds in the treatment of Glioblastomas, Chemotherapy and other cancer applications."
Doug Bonhaus, CEO of Neuropore Therapies, commented, "While Neuropore Therapies continues to explore the therapeutic potential of autophagy modulators for neurodegenerative disorders, we are very pleased to see the therapeutic potential of these PI3K and VPS34 targeted compounds pursued for additional indications."
Visit Global Cancer Technology’s website to learn more about the company and their technologies: https://www.globalcancertechnology.com/
To learn more about the PI3K inhibitor, please download the slide deck below.